echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Merck's new crown oral drug Molnupiravir submits EUA to FDA

    Merck's new crown oral drug Molnupiravir submits EUA to FDA

    • Last Update: 2021-10-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On October 11, Merck announced that it had submitted an emergency authorization application (EUA) for the oral antiviral drug Molnupiravir (MK-4482) to the FDA


    From: Merck official website

    The EUA is based on the positive interim analysis results of the Phase 3 clinical MOVe-OUT study


    In terms of safety, the incidence of any adverse events in the Molnupiravir group and the placebo group was similar (35% and 40%, respectively), and the incidence of drug-related adverse events was also the same (12% and 11%, respectively)


    At the beginning of this year, Merck has reached a procurement agreement with the US government


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.